1-(3,4-二甲基苯基)哌嗪 | 1014-05-7

• 物质功能分类: 医药中间体 - 杂环化合物 - 哌嗪类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-(3,4-二甲基苯基)哌嗪
• 中文别名: 1-(3,4-甲氧基苯基)哌嗪；1-(3,4-二甲基苯基)哌嗪盐酸盐
• 英文名称: 1-(3,4-dimethylphenyl)piperazine
• 英文别名: 3,4-dimethyl phenyl piperazine
• CAS: 1014-05-7
• 化学式: C₁₂H₁₈N₂
• mdl: MFCD00023129
• 分子量: 190.288
• InChiKey: SFLNVAVCCYTHCQ-UHFFFAOYSA-N

物化性质

• 熔点：
  60-65°C
• 沸点：
  110 °C
• 密度：
  1.0320 (rough estimate)
• 闪点：
  175°C/10mm
• 稳定性/保质期：
  常温常压下稳定，避免与空气直接接触以防氧化。

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  8
• 危险品标志：
  Xi
• 安全说明：
  S24/25
• 危险类别码：
  R36/37/38
• 海关编码：
  2933599090
• 危险品运输编号：
  3259
• 危险类别：
  8
• 包装等级：
  II
• 储存条件：
  在干燥的惰性气体中保持容器密封，并存放在阴凉、干燥处。

SDS

Name:	1-(3 4-Dimethylphenyl)piperazine 98+% Material Safety Data Sheet
Synonym:	None known
CAS:	1014-05-7

Section 1 - Chemical Product MSDS Name:1-(3 4-Dimethylphenyl)piperazine 98+% Material Safety Data Sheet
Synonym:None known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
1014-05-7	1-(3,4-Dimethylphenyl)piperazine	>98	213-798-2

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. The toxicological properties of this substance have not been fully investigated.
Inhalation:
Causes respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. Can produce delayed pulmonary edema.
Chronic:
Effects may be delayed.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 1014-05-7: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: faint yellow
Odor: none reported
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 61.00 - 65.00 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C12H18N2
Molecular Weight: 190.29

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 1014-05-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-(3,4-Dimethylphenyl)piperazine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 1014-05-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 1014-05-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 1014-05-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

应用1-(3,4-二甲基苯基)哌嗪可作为有机合成中间体和医药中间体，主要应用于实验室研发及化工生产过程。

反应信息

• 作为反应物：
  描述：

  1-(3,4-二甲基苯基)哌嗪 以 乙醚 为溶剂， 生成 4-(3,4-dimethylphenyl)-N-5-isoquinolinyl-1-piperazinecarboxamide
  参考文献：
  名称：

  Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

  摘要：

  式（I）的化合物是新颖的VR1拮抗剂，可用于治疗疼痛、炎症性热性过敏、尿失禁和膀胱过度活动。

  公开号：

  US20040157849A1
• 作为产物：
  描述：

  在 水 、 sodium thiosulfate 作用下， 以 乙腈 为溶剂， 反应 2.0h， 生成 1-(3,4-二甲基苯基)哌嗪
  参考文献：
  名称：

  电荷转移指导的自由基取代可实现对选择性的C–H功能化

  摘要：

  高效的C–H功能化要求对特定的C–H键具有选择性。定向芳族取代反应实现邻位和间位选择性已取得进展，但对位选择性C–H功能化的一般策略仍然难以捉摸。在这里，我们介绍一个以前不受重视的概念，使几乎完全对选择性。我们建议具有高电子亲和力的自由基在自由基加成的过渡态中引起芳烃到自由基的电荷转移，这是主要负责高位置选择性的因素。我们用简单的理论工具论证了选择性是可预测的，并通过直接合成芳基哌嗪显示了该概念的实用性。我们的结果与有机化学家普遍认为的自由基芳族取代反应本质上是非选择性的观点相矛盾。由电荷转移指导的自由基取代的概念可以作为开发新的，高度选择性的CHH功能化反应的基础。

  DOI：

  10.1038/nchem.2529

文献信息

• Dopamine D4 receptor antagonists
  申请人：Warner-Lambert Company

  公开号：US06087364A1

  公开（公告）日：2000-07-11

  Compounds that are antagonists of dopamine D4 receptors, methods of treating psychosis and schizophrenia using the compounds, and pharmaceutically acceptable compositions that contain the dopamine D4 receptor antagonists are disclosed.

  抗多巴胺D4受体的化合物，使用这些化合物治疗精神病和精神分裂症的方法，以及含有多巴胺D4受体拮抗剂的药学上可接受的组合物被披露。
• Design, synthesis, and biological evaluation of structurally constrained hybrid analogues containing ropinirole moiety as a novel class of potent and selective dopamine D3 receptor ligands
  作者：Benhua Zhou、Kwon Ho Hong、Min Ji、Jin Cai

  DOI：10.1111/cbdd.13324

  日期：2018.9

  evaluated as a novel class of selective ligands for the dopamine D3 receptor. Binding affinities of target compounds were determined (using the method of radioligand binding assay). Compared to comparator agent BP897, compounds 2a and 2c were found to demonstrate a considerable binding affinity and selectivity for D3 receptor, and especially compound 2h was similarly potent and more selective D3R ligand than

  设计，合成和评估了两个系列的杂合类似物，作为多巴胺D3受体的一类新的选择性配体。确定目标化合物的结合亲和力（使用放射性配体结合测定法）。与比较剂BP897相比，发现化合物2a和2c对D3受体表现出相当大的结合亲和力和选择性，尤其是化合物2h与BP897（正参比）具有相似的效力和更高的D3R配体。因此，它们可以为发现和开发具有出色选择性的高效多巴胺D3受体配体提供有价值的信息。
• [EN] 1-ARYL-4-SUBSTITUTED PIPERAZINES DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS<br/>[FR] DERIVES DE PIPERAZINES 1-ARYL-4-SUSBTITUES UTILISES EN TANT QU'ANTAGONISTES DU CCR1 DANS LE TRAITEMENT DE L'INFLAMMATION ET DES TROUBLES IMMUNITAIRES
  申请人：CHEMOCENTRYX INC

  公开号：WO2003105853A1

  公开（公告）日：2003-12-24

  Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

  提供了作为CCR1受体强效拮抗剂的化合物，并且已经在动物炎症测试中进一步确认，炎症是CCR1的典型疾病状态之一。这些化合物通常是芳基哌嗪衍生物，在制药组合物、治疗CCR1介导疾病的方法以及用于鉴定竞争性CCR1拮抗剂的检测中具有用途。
• [EN] QUINOLONE CARBOXYLIC ACID DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE CONDITIONS<br/>[FR] DERIVES D'ACIDE CARBOXYLIQUE DE QUINOLONE POUR LE TRAITEMENT DES TROUBLES HYPERPROLIFERATIFS
  申请人：BAYER PHARMACEUTICALS CORP

  公开号：WO2005097752A1

  公开（公告）日：2005-10-20

  Quinolone carboxylic acid derivatives of formula (I) wherein Ar is an optionally substituted phenyl, pyridyl, or pyrimidinyl group and the substituent groups R1, R4, R10, R11, R19, and R20 are as defined in the specification, pharmaceutical compositions containing them, and methods of using them in treatment of hyperproliferative diseases such as cancer are disclosed and claimed.

  公开和声明了式(I)的喹诺酮羧酸衍生物，其中Ar是可选择地取代的苯基、吡啶基或嘧啶基，取代基R1、R4、R10、R11、R19和R20如规范中定义，包含它们的药物组合物，以及在治疗癌症等高增殖性疾病中使用它们的方法。
• Iridium-Catalyzed Asymmetric Ring-Opening of Oxabenzonorbornadienes with N-Substituted Piperazine Nucleophiles
  作者：Wen Yang、Renshi Luo、Dingqiao Yang

  DOI：10.3390/molecules201219748

  日期：——

  Iridium-catalyzed asymmetric ring-opening of oxabenzonorbornadienes with N-substituted piperazines was described. The reaction afforded the corresponding ring-opening products in high yields and moderate enantioselectivities in the presence of 2.5 mol % [Ir(COD)Cl]2 and 5.0 mol % (S)-p-Tol-BINAP. The effects of various chiral bidentate ligands, catalyst loading, solvent, and temperature on the yield and enantioselectivity were also investigated. A plausible mechanism was proposed to account for the formation of the corresponding trans-ring opened products based on the X-ray structure of product 2i.

  报道了铱催化的氧杂苯并降冰片二烯与N-取代哌嗪的不对称开环反应。在2.5 mol% [Ir(COD)Cl]2和5.0 mol% (S)-对甲苯-BINAP的存在下，该反应以高产率和中等对映选择性提供了相应的开环产物。还研究了各种手性双齿配体、催化剂用量、溶剂和温度对产率和对映选择性的影响。基于产物2i的X射线结构，提出了一个合理的机理来解释相应反式开环产物的形成。